FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Laleh Amiri‐Kordestani(United States Food and Drug Administration), Patricia Cortazar(Center for Drug Evaluation and Research), Amna Ibrahim(Beni-Suef University), Nitin Mehrotra(Center for Drug Evaluation and Research), Gideon M. Blumenthal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Reyes Candau-Chacon(Center for Drug Evaluation and Research), Kathleen A. Clouse(United States Food and Drug Administration), Robert Justice(United States Food and Drug Administration), Anne‐Marie Russell(Birmingham City University), Shenghui Tang(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Todd R. Palmby(University of North Carolina at Chapel Hill), Sarah J. Schrieber(Center for Drug Evaluation and Research), Wendy C. Weinberg(United States Food and Drug Administration), Pengfei Song(Henan University), Ali Al‐Hakim(Center for Drug Evaluation and Research), Sarah Pope Miksinski(Center for Drug Evaluation and Research), Jian Wang(Capital Medical University), Qi Liu(United States Food and Drug Administration), Qiang Xu(Wannan Medical College), Bo Chi(Center for Biologics Evaluation and Research), Rajeshwari Sridhara(Center for Drug Evaluation and Research), P. E. Hughes(Center for Drug Evaluation and Research), Linan Ha(Center for Biologics Evaluation and Research), Lisa Skarupa(National Institutes of Health), Lijun Zhang(Dalian Medical University), W. David McGuinn(United States Food and Drug Administration)
Cited by 350
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k